KCTD2

Across TCGA pan-cancer cohorts, KCTD2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated KCTD2 data layer compared with 21 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher KCTD2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated KCTD2 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

HNSC, CCRCC, and PDAC are the cancer types where KCTD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	II,III,IV	1.000	0.475	.013	12	view →
CCRCC	DFS	Median	III,IV	0.274	0.974	.005	9	view →
PDAC	DFS	Median	II,III,IV	0.228	0.461	.013	4	view →
LUAD	DFS	Quartile	II,III,IV	0.537	0.988	.027	2	view →
LSCC	OS	Quartile	All	0.607	1.000	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

KCTD2–HNSC (DFS)

Open the HNSC breakdown →